Lymphoma, T-Cell, Peripheral clinical trials

The registry lists 372 studies for Lymphoma, T-Cell, Peripheral across more than 10 countries. 110 are recruiting or about to start. 234 of them are mainly about Lymphoma, T-Cell, Peripheral (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Lymphoma, T-Cell, Peripheral studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 139
Recruiting: 76
Status unknown: 46
Terminated: 46
Not yet recruiting: 29
Active, not recruiting: 17

Phase

Phase 2: 193
Phase 1: 150
Phase 3: 27
Early Phase 1: 9
Phase 4: 5

Where

United States: 164
China: 114
Italy: 35
France: 29
Spain: 25
United Kingdom: 20

Who runs them

National Cancer Institute (NCI) (16) · Ruijin Hospital (14) · Fred Hutchinson Cancer Center (14) · Sun Yat-sen University (10) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (9) · Acrotech Biopharma Inc. (7) · Fudan University (6) · Peking Union Medical College Hospital (5)

What is being tested here

Drugs under test in Lymphoma, T-Cell, Peripheral studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Tucidinostat	13	2	25
Golidocitinib	13	3	16
Azacitidine	7	0	11
Zeprumetostat	6	0	7
Linperlisib	5	1	7
Cyclophosphamide	4	1	15
Prednisone	4	1	10
Lenalidomide	3	0	13
Brentuximab Vedotin	3	1	11
Pembrolizumab	3	0	5

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 20 open · JAK inhibitors 18 open · HDAC inhibitors 13 open · Immune checkpoint inhibitors 11 open · Antimetabolites 9 open

Coming up

15phase 3 studies under way

30studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2027Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · Phase 3 · Corvus Pharmaceuticals, Inc.
Nov 2027A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) · Phase 3 · Dizal Pharmaceuticals
Nov 2026Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Nov 2026A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma · Treeline Biosciences, Inc.
Dec 2026A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL · Sun Yat-sen University
Dec 2026Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · Children's Hospital Medical Center, Cincinnati
Dec 2026Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma · Fudan University
Dec 2026Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma · Institute of Hematology & Blood Diseases Hospital, China
Dec 2026Circulating Tumor DNA in Peripheral T-cell Lymphomas · University of Aarhus
Dec 2026Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) · Sun Yat-Sen University Cancer Center

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger. 5 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 76
Age	Women	Men
10	2 (3%)	2 (3%)
18	73 (96%)	73 (96%)
30	75 (99%)	75 (99%)
40	73 (96%)	73 (96%)
50	73 (96%)	73 (96%)
65	73 (96%)	73 (96%)
75	56 (74%)	56 (74%)
85	34 (45%)	34 (45%)

Across all 372 studies, recruiting or not: 31% stop at 75 or younger and 8% at 65; 13% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, T-Cell, Peripheral studies take

Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	49 mo33–61 · 42 studies	—	—
Phase 1/2	49 mo39–65 · 31 studies	—	—
Phase 2	61 mo38–96 · 64 studies	—	65 mo47–110 · 44 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered2

Allogeneic Cell Therapy in Refractory T-Cell LymphomaNov 5, 2026NCT07920393
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsOct 27, 2026NCT07899632

Studies

Recruiting first, then most recently updated. Showing 50 of 372. Browse all 372 → or search them.